

10<sup>th</sup> Global Summit on

# IMMUNOLOGY AND CELL BIOLOGY

May 11-12, 2018 Osaka, Japan

## Ensuring the quality and efficacy of *Haemophilus influenzae* b vaccines - The UK experience

**Fatme Mawas**

National Institute for Biological Standards & Control- MHRA, UK

*Haemophilus influenzae* type b (Hib) was a leading cause of meningitis in infants in the UK until October 1992, when Hib conjugate vaccine was introduced for children at age 2, 3, and 4 months. Quality control testing of the vaccine is very important to ensure the quality, safety and efficacy of the vaccine. Here, we describe our experience at the UK National Institute for Biological standards & Control in the testing and investigation of quality and efficacy of Hib vaccines in monovalent formulations and in combination with other vaccines such as meningococcal C or DTP-based combination vaccines.

Fatme.Mawas@nibsc.org

Notes: